What is the 13F Pro Quality Score for AVDL?

13F Pro ranks AVADEL PHARMACEUTICALS PLC (AVDL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AVDL's current score at https://13fpro.ai/company/AVDL (free sign-up required for the full ranking).

Where does 13F Pro source AVDL data?

All AVADEL PHARMACEUTICALS PLC fundamentals and ownership data come directly from SEC EDGAR. AVADEL PHARMACEUTICALS PLC files with the SEC under CIK 1012477. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AVDL in?

AVADEL PHARMACEUTICALS PLC (AVDL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AVDL research updated on 13F Pro?

AVDL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AVADEL PHARMACEUTICALS PLC(AVDL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1012477 AVDL stock profile & AI dashboard →

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

56.7/100

Rank #1,059 of 2,856 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why AVDL Scores 57/100

exact factor attribution · 2026-07-01

AVDL's composite is driven by revenue growth and earnings quality, held back by scale and institutional flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.6 pts

98th pct

Earnings quality

+4.7 pts

97th pct

Free cash flow

+2.6 pts

67th pct

Profitability

+0.2 pts

51th pct

Earnings growth

-1.0 pts

30th pct

Capital efficiency

-1.5 pts

35th pct

Shareholder dilution

-1.8 pts

14th pct

Institutional flow

-2.4 pts

2th pct

Scale

-3.6 pts

26th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

AVDL Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for AVADEL PHARMACEUTICALS PLC (AVDL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AVDL at 56.7/100 on a 32-signal composite quality model, placing it at rank #1,059 of 2,856 stocks — the top half of the AI-ranked universe. Based on the latest XBRL financial filings (Q3 2025), AVADEL PHARMACEUTICALS PLC reports quarterly revenue of $77.5M, net income of $20.0K, an operating margin of 2.5%. AVDL trades on the Nasdaq exchange and files with the SEC under CIK 1012477. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVDL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AVADEL PHARMACEUTICALS PLC directly from SEC EDGAR. AVADEL PHARMACEUTICALS PLC's 13F Pro composite quality score has ranged between 57 and 58 since 2026, currently 56.7 — a stable long-term trajectory across 36 quarterly and live scoring snapshots.

Revenue

Q3 2025

$77.5M

Net Income

Q3 2025

$20.0K

Free Cash Flow

Q3 2025

$22.2M

Operating Margin

Q3 2025

2.5%

ROIC

Q3 2025

7.9%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+504.8% YoY

$169.1MFY 2024

FY21 $0.00FY22 $0.00FY23 $28.0MFY24 $169.1M

Net Income

+69.5% YoY

$-48.8MFY 2024

FY21 $-77.3MFY22 $-137.5MFY23 $-160.3MFY24 $-48.8M

Operating Income

+69.2% YoY

$-42.4MFY 2024

FY21 $-85.5MFY22 $-98.6MFY23 $-137.8MFY24 $-42.4M

EPS (Diluted)

+74.5% YoY

$-0.51FY 2024

FY21 $-1.32FY22 $-2.29FY23 $-2.00FY24 $-0.51

Total Assets

-0.3% YoY

$164.2MFY 2024

FY21 $247.3MFY22 $132.8MFY23 $164.7MFY24 $164.2M

Total Debt

—FY 2024

FY21 $142.4MFY22 $129.3MFY23 —FY24 —

Op. Cash Flow

+63.5% YoY

$-46.9MFY 2024

FY21 $-77.3MFY22 $-70.3MFY23 $-128.5MFY24 $-46.9M

Free Cash Flow

+63.5% YoY

$-46.9MFY 2024

FY21 $-77.3MFY22 $-71.0MFY23 $-128.5MFY24 $-46.9M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$169.1M +504.8%	$28.0M	$0.00	$0.00 -100.0%	$22.3M -62.3%	$59.2M
Net Income	$-48.8M +69.5%	$-160.3M -16.6%	$-137.5M -77.8%	$-77.3M -1200.3%	$7.0M +121.2%	$-33.2M
Operating Income	$-42.4M +69.2%	$-137.8M -39.9%	$-98.6M -15.2%	$-85.5M -1571.1%	$5.8M +124.1%	$-24.1M
EPS (Diluted)	$-0.51 +74.5%	$-2.00 +12.7%	$-2.29 -73.5%	$-1.32 -1115.4%	$0.13 +114.6%	$-0.89
Total Assets	$164.2M -0.3%	$164.7M +24.0%	$132.8M -46.3%	$247.3M -20.7%	$311.6M +105.8%	$151.4M
Total Debt	—	—	$129.3M -9.2%	$142.4M +11.1%	$128.2M +5.4%	$121.7M
Operating Cash Flow	$-46.9M +63.5%	$-128.5M -82.8%	$-70.3M +9.1%	$-77.3M -58.6%	$-48.7M -27.2%	$-38.3M
Free Cash Flow	$-46.9M +63.5%	$-128.5M -81.0%	$-71.0M +8.2%	$-77.3M -58.4%	$-48.8M -27.3%	$-38.4M

Get alerted when AVDL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AVADEL PHARMACEUTICALS PLC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AVDL

HUNTINGTON NATIONAL BANK
$16.001 sh

Fund	Value	Shares
HUNTINGTON NATIONAL BANK	$16.00	1

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AVDL on your watchlist

Track score changes the day AVADEL PHARMACEUTICALS PLC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AVDL a good stock to buy?

13F Pro's AI-powered analysis of AVADEL PHARMACEUTICALS PLC (AVDL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AVDL are available on the AVDL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AVDL is classified as a mid company.

Which hedge funds own AVDL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AVDL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AVADEL PHARMACEUTICALS PLC's investment landscape.